Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 9/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.42 |
| ▸ | PTGES | O14684 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | FYN | P06241 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1970301 | 0.92 | MTOR (0.45) | LCKKMT2ANPC1RAB9AMEN1 | |
| SCHEMBL13393315 | 0.92 | MAOB (0.44) | LCKKMT2ANPC1RAB9AMEN1 | |
| SCHEMBL1971730 | 0.89 | ALDH1A1 (0.54) | LCKKMT2ANPC1RAB9APTGES | |
| SCHEMBL1972260 | 0.87 | KMT2A (0.57) | KMT2ANPC1RAB9AMEN1PTGES | |
| SCHEMBL1969829 | 0.86 | LCK (0.53) | LCKKMT2ANPC1RAB9AMEN1 | |
| SCHEMBL1336288 | 0.85 | PTGES (0.43) | LCKHDAC11PTGESSRC | |
| SCHEMBL13392916 | 0.85 | SORT1 (0.45) | LCKKMT2ANPC1RAB9AMEN1 | |
| SCHEMBL1974207 | 0.85 | NPC1 (0.54) | LCKKMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1974445 | 0.85 | KMT2A (0.50) | LCKKMT2ANPC1RAB9AMEN1 | |
| SCHEMBL13393168 | 0.85 | KMT2A (0.47) | LCKKMT2ANPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2334652-A1 | 1H-BENZ IMIDAZOLE-5-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS | Boehringer Ingelheim International GmbH (DE) | 2011-06-22 | — | — | EP | claimed |
| US-8916599-B2 | 1H-benz imidazole-5-carboxamides as anti-inflammatory agents | OREXO AB (SE) | 2014-12-23 | — | — | US | disclosed |
| US-20110312935-A1 | 1H-Benz Imidazole-5-Carboxamides As Anti-Inflammatory Agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312935-A1 | 1H-Benz Imidazole-5-Carboxamides As Anti-Inflammatory Agents | MAPRE2, MAPRE1, H1-4 | LCK 1306/4885KMT2A 1047/4885NPC1 4650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.